Indo US Bio-Tech (NSE:INDOUS) Asset Turnover: 0.20 (As of Mar. 2026)


NSE:INDOUS Indo US Bio-Tech Ltd NSE:INDOUS
63 GF Score
Price ₹89.15
GF Value ₹292.08
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Indo US Bio-Tech Asset Turnover?

Indo US Bio-Tech NSE:INDOUS +0.96% 63 Asset Turnover is 0.20 as of Mar. 2026. GuruFocus rates NSE:INDOUS with a GF Score™ of 63/100 and a GF Value™ of ₹292.08 (Possible Value Trap). The stock has 5 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Indo US Bio-Tech's Revenue for the three months ended in Mar. 2026 was ₹260 Mil. Indo US Bio-Tech's Total Assets for the quarter that ended in Mar. 2026 was ₹1,331 Mil. Therefore, Indo US Bio-Tech's Asset Turnover for the quarter that ended in Mar. 2026 was 0.20.

Asset Turnover is linked to ROE % through Du Pont Formula. Indo US Bio-Tech's annualized ROE % for the quarter that ended in Mar. 2026 was 8.52%. It is also linked to ROA % through Du Pont Formula. Indo US Bio-Tech's annualized ROA % for the quarter that ended in Mar. 2026 was 5.93%.


Indo US Bio-Tech  (NSE:INDOUS) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Indo US Bio-Tech's annulized ROE % for the quarter that ended in Mar. 2026 is

ROE %**(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=78.868/925.339
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(78.868 / 1040.988)*(1040.988 / 1330.967)*(1330.967/ 925.339)
=Net Margin %*Asset Turnover*Equity Multiplier
=7.58 %*0.7821*1.4384
=ROA %*Equity Multiplier
=5.93 %*1.4384
=8.52 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Indo US Bio-Tech's annulized ROA % for the quarter that ended in Mar. 2026 is

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=78.868/1330.967
=(Net Income / Revenue)*(Revenue / Total Assets)
=(78.868 / 1040.988)*(1040.988 / 1330.967)
=Net Margin %*Asset Turnover
=7.58 %*0.7821
=5.93 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Indo US Bio-Tech Asset Turnover Related Terms


Indo US Bio-Tech Asset Turnover Historical Data

* Premium members only.

The historical data trend for Indo US Bio-Tech's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indo US Bio-Tech Asset Turnover Chart

Indo US Bio-Tech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.01 0.99 0.95 1.14 0.96

Indo US Bio-Tech Quarterly Data
Mar20 Sep20 Mar21 Sep21 Mar22 Jun22 Sep22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.31 0.26 0.20 0.20

NSE:INDOUS vs CTVA, CF, MOS: Asset Turnover Comparison

For the Agricultural Inputs subindustry, Indo US Bio-Tech's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indo US Bio-Tech Asset Turnover vs Agriculture Industry

For the Agriculture industry and Basic Materials sector, Indo US Bio-Tech's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Indo US Bio-Tech's Asset Turnover falls into.


NSE:INDOUS
63GF Score
Indo US Bio-Tech Ltd NSE:INDOUS
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indo US Bio-Tech Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Indo US Bio-Tech's Asset Turnover for the fiscal year that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2026 )/( (Total Assets (A: Mar. 2025 )+Total Assets (A: Mar. 2026 ))/ count )
=1104.391/( (978.427+1330.967)/ 2 )
=1104.391/1154.697
=0.96

Indo US Bio-Tech's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=260.247/( (0+1330.967)/ 1 )
=260.247/1330.967
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.20 mean?
Indo US Bio-Tech (NSE:INDOUS) has a Asset Turnover of 0.20 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Indo US Bio-Tech and its competitors.
Is Indo US Bio-Tech's Asset Turnover too high?
Indo US Bio-Tech's current Asset Turnover is 0.20. Overall, Indo US Bio-Tech has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indo US Bio-Tech's Asset Turnover compare to CTVA and CF?
Indo US Bio-Tech's Asset Turnover of 0.20 can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for an Agriculture company?
A good Asset Turnover depends on the Agriculture industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Indo US Bio-Tech and its competitors. Indo US Bio-Tech's current Asset Turnover is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo US Bio-Tech stock overvalued right now?
Based on GuruFocus' analysis, Indo US Bio-Tech (NSE:INDOUS) is currently considered Possible Value Trap. The stock's GF Value™ is ₹292.08, compared to a current price of ₹89.15 — trading 69.5% below its estimated fair value. The current Asset Turnover is 0.20. Indo US Bio-Tech's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Indo US Bio-Tech (NSE:INDOUS), the current Asset Turnover is 0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indo US Bio-Tech (NSE:INDOUS) Overvalued in 2026?

Based on GuruFocus' analysis, Indo US Bio-Tech stock appears to be undervalued. The current stock price of ₹89.15 is trading 69.5% below its estimated GF Value™ of ₹292.08. GuruFocus considers Indo US Bio-Tech to be Possible Value Trap.

Key valuation signals for NSE:INDOUS:

  • Asset Turnover: 0.20
  • GF Value™: ₹292.08 vs. price of ₹89.15 (69.5% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the NSE:INDOUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Indo US Bio-Tech Business Description

Other Exchanges 541304:India
Address Satadhar Char Rasta, Sola Road, 309, Shanti Mall, Opposite Navrang Tower, Ahmedabad, GJ, IND, 380061
Indo US Bio-Tech Ltd is a specialized agriculture seed company. It is involved in crop research and development through breeding, production of seeds, processing, packing, and marketing of high-performing hybrid and open-pollinated varieties of crops. The company's product portfolio includes a diversified variety of agricultural seeds, namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds of vegetables, pulses, crops like tomato, okra, brinjal, onion, bit root, cucumber, bottle gourd, groundnut, mustard, bajra, wheat, etc.
63GF Score

Get the complete analysis for NSE:INDOUS

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹89.15
Price
₹292.08
GF Value